Clinical Trial Update: Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating degarelix as second-line hormonal therapy after PSA failure in men previously treated with GnRH agonists for prostate cancer. Results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• degarelix (degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-01-18